ArticleFrontiers in aging neuroscience2025
Investigation of gray matter volume in individuals with heart failure and preserved ejection fraction.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Object: This study employs voxel-based morphometry techniques to identify potential areas of brain injury in patients with heart failure with preserved ejection fraction (HFpEF). It further assesses the correlation between clinical indicators, cardiac function parameters, and gray matter volume (GMV). This provides an imaging-based anatomical biomarker for in-depth research into the brain structure in patients with HFpEF. Materials and methods: This study recruited 51 patients with HFpEF (26 males and 25 females) and 40 healthy controls (27 males and 13 females). Data on NT-proBNP levels, echocardiographic parameters, and cognitive function scores were collected for both groups. High-resolution 3D T1-weighted imaging (3D-T1WI) structural MRI data were collected from all participants. The changes in GMV between the two groups were assessed using voxel-based morphometry (VBM). Results: The study involved 40 patients with HFpEF and 28 healthy controls (HC). No significant differences were observed between the groups regarding age, gender, education, or BMI. The HFpEF group exhibited larger measurements for Left Ventricular Posterior Wall (LVPW), Interventricular Septal Thickness (IVST), Left Atrial Diameter (LAD), Right Atrial Diameter (RAD), and Right Ventricular Diameter (RVD). However, they maintained preserved systolic function and achieved lower scores on the MoCA, indicating deficits in visuospatial/executive functions, naming, attention, language, and memory. Compared to HC, HFpEF patients had reduced GMV in specific brain regions. NT-proBNP levels were negatively correlated with GM reduction in various cerebellar, frontal, temporal, and postcentral regions. Cognitive performance was inversely related to GM shrinkage, with different brain regions correlating with specific cognitive deficits. Conclusion: Abnormalities in GMV in several brain areas have been identified in patients with HFpEF. Furthermore, these abnormal GMV are associated with NT-proBNP levels, echocardiographic indices, and neurocognitive scoring. These observations could provide fresh perspectives on the pathogenic mechanisms of HFpEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.